A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of HJB647 in Participants With Chronic Stable Heart Failure With Reduced Ejection Fraction
Latest Information Update: 17 Mar 2026
At a glance
- Drugs HJB 647 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Novartis
Most Recent Events
- 17 Mar 2026 New trial record